Investing.com - POINT Biopharma Global reported on Monday third quarter earnings that missed analysts' forecasts and revenue that topped expectations.
POINT Biopharma Global announced earnings per share of $-0.860 on revenue of $869.7K. Analysts polled by Investing.com anticipated EPS of $-0.282 on revenue of $0.
POINT Biopharma Global shares are down 19.03% from the beginning of the year and are trading at $9.000 , down-from-52-week-high.
POINT Biopharma Global shares lost 1.53% in pre-market trade the report.
POINT Biopharma Global follows other major Healthcare sector earnings this month
POINT Biopharma Global's report follows an earnings beat by J&J on Tuesday, October 18, 2022, who reported EPS of $2.55 on revenue of $23.79B, compared to forecasts EPS of $2.48 on revenue of $23.36B.
Eli Lilly had beat expectations on Tuesday, November 1, 2022 with third quarter EPS of $1.98 on revenue of $6.94B, compared to forecast for EPS of $1.91 on revenue of $6.91B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar